These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 32083035)
21. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. Elsadek HM; Abdelbaser ES; Emara MH; Soliman HH; Farag AA Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):1046-1053. PubMed ID: 33216478 [TBL] [Abstract][Full Text] [Related]
22. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976 [TBL] [Abstract][Full Text] [Related]
23. Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4. Ahmed S; Hassan E; Gomaa A; Esamat G; Ramadan A; Ahmed M; Elsayed A; A Wahsh E Curr Drug Saf; 2023; 18(2):207-213. PubMed ID: 35538812 [TBL] [Abstract][Full Text] [Related]
24. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Goel A; Bhadauria DS; Kaul A; Verma A; Tiwari P; Rungta S; Rai P; Gupta A; Aggarwal R Nephrol Dial Transplant; 2021 Sep; 36(10):1867-1871. PubMed ID: 33097949 [TBL] [Abstract][Full Text] [Related]
25. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Huang CF; Dai CY; Yeh ML; Huang CI; Lee HC; Lai WT; Liang PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Chuang WL; Yu ML Kaohsiung J Med Sci; 2020 Nov; 36(11):920-928. PubMed ID: 32643842 [TBL] [Abstract][Full Text] [Related]
26. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846 [TBL] [Abstract][Full Text] [Related]
27. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals. Chen YC; Li CH; Ko PH; Lee CC; Syu RJ; Tseng CW; Tseng KC PLoS One; 2021; 16(8):e0256505. PubMed ID: 34437608 [TBL] [Abstract][Full Text] [Related]
28. Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin). Wahid B; Shami K; Joiya SA; Özuyar SEG; Idrees M J Med Virol; 2020 Dec; 92(12):3868-3870. PubMed ID: 32419178 [TBL] [Abstract][Full Text] [Related]
29. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162 [TBL] [Abstract][Full Text] [Related]
30. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents. Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658 [TBL] [Abstract][Full Text] [Related]
31. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329 [TBL] [Abstract][Full Text] [Related]
33. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major. Nagral A; Jhaveri A; Sawant S; Parikh NS; Nagral N; Merchant R; Gandhi M Indian J Pediatr; 2019 Feb; 86(2):148-153. PubMed ID: 30097845 [TBL] [Abstract][Full Text] [Related]
34. Peripheral Expression of Afzal M; Ali A; Sheikh N; Rafique S; Idrees M J Interferon Cytokine Res; 2020 Jun; 40(6):301-309. PubMed ID: 32486887 [TBL] [Abstract][Full Text] [Related]
35. Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study. Ahmed EI; Abdel Wahed WY; Hassan EA; Ahmed TI Curr Drug Saf; 2018; 13(3):187-195. PubMed ID: 30009714 [TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability. Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537 [TBL] [Abstract][Full Text] [Related]
38. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. Colombo M; Aghemo A; Liu H; Zhang J; Dvory-Sobol H; Hyland R; Yun C; Massetto B; Brainard DM; McHutchison JG; Bourlière M; Peck-Radosavljevic M; Manns M; Pol S Ann Intern Med; 2017 Jan; 166(2):109-117. PubMed ID: 27842383 [TBL] [Abstract][Full Text] [Related]
39. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia. Zhang M; O'Keefe D; Iwamoto M; Sann K; Kien A; Hang V; Brucker C; Jolivet P; Ly S; Chhit D; Balkan S; Marquardt T; Le Paih M; Dousset JP J Viral Hepat; 2020 Sep; 27(9):886-895. PubMed ID: 32358826 [TBL] [Abstract][Full Text] [Related]
40. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]